TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11283379

Group type: EXPERIMENTAL
Intervention: Intima-media thickness (IMT) in common carotid artery (CCA)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Resistive index (RI) in common carotid artery (CCA)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Resistive index (RI) in internal carotid artery (ICA)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: SMART atherosclerosis risk score
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Correlation between SMART atherosclerosis score and IMT CCA
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Correlation between SMART atherosclerosis score and RI ICA
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Correlation between SMART atherosclerosis score and RI CCA
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Receiver operating curve for IMT
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Receiver operating curve for RI ICA
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Receiver operating curve for RI CCA
Number of subjects: 157
Study: 9093988

Group type: EXPERIMENTAL
Intervention: 0 g CPP
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 1 g CPP
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 2 g CPP
Number of subjects: 22

Group type: COMPARATOR
Intervention: 0 g CPP (whole-grain cereal)
Number of subjects: 22

Group type: COMPARATOR
Intervention: 1 g CPP (whole-grain cereal)
Number of subjects: 22

Group type: COMPARATOR
Intervention: 2 g CPP (whole-grain cereal)
Number of subjects: 22
Study: 7909874

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemeprost
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 2834938

Group type: EXPERIMENTAL
Intervention: Enalaprilat (intravenous)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 12
Study: 29381802

Group type: EXPERIMENTAL
Intervention: Glucose-containing beverage (75 g glucose dissolved in 300 mL water) at 22°C
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Glucose-containing beverage (75 g glucose dissolved in 300 mL water) at 0°C
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Plain tap water at room temperature (22°C)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Plain tap water at 0°C
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: All stimuli (glucose at 0°C, glucose at 22°C, water at 0°C)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Plain water (all temperatures)
Number of subjects: 16
Study: 27924501

Group type: EXPERIMENTAL
Intervention: Behavioral intervention including two lectures and printed resources (behavior cards, educational sheets)
Number of subjects: 1138

Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 1138

Group type: COMPARATOR
Intervention: Control group following usual health education curriculum
Number of subjects: 1138
Study: 26065720

Group type: EXPERIMENTAL
Intervention: CPAP plus conservative care (CC) for 3 months
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conservative care (CC)
Number of subjects: 33
Study: 22900794

Group type: EXPERIMENTAL
Intervention: Computer controlled 'Anaeject' device
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional syringe
Number of subjects: 100
Study: 21724782

Group type: EXPERIMENTAL
Intervention: Critical Time Intervention (CTI)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study: 19195513

Group type: EXPERIMENTAL
Intervention: ABT-335 + atorvastatin 20 mg
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: ABT-335 + atorvastatin 40 mg
Number of subjects: 613

Group type: COMPARATOR
Intervention: Atorvastatin 20 mg
Number of subjects: 613

Group type: COMPARATOR
Intervention: Atorvastatin 40 mg
Number of subjects: 613

Group type: COMPARATOR
Intervention: ABT-335
Number of subjects: 613
Study: 16867927

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Slow-release morphine
Number of subjects: 14
Study: 15309292

Group type: EXPERIMENTAL
Intervention: Intervention group (lifestyle intervention)
Number of subjects: 506

Group type: COMPARATOR
Intervention: Control group (no lifestyle intervention)
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Subgroup with FSIGT (n=83)
Number of subjects: 506
Study: 11349176

Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Penicillin G
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Ampicillin and Penicillin G
Number of subjects: 574
Study: 7537779

Group type: EXPERIMENTAL
Intervention: Surface anesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conduction anesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indomethacin (control for nonspecific phenomena)
Number of subjects: 0
Study: 2693136

Group type: EXPERIMENTAL
Intervention: Otrivine-Antistin eyedrops
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 326052

Group type: EXPERIMENTAL
Intervention: Acetazolamide (Diamox) administered to 24 eyes
Number of subjects: 49

Group type: COMPARATOR
Intervention: Untreated eyes (control group)
Number of subjects: 49
Study: 30855723

Group type: EXPERIMENTAL
Intervention: Tapentadol immediate release (IR)
Number of subjects: 1447
Study: 26932733

Group type: EXPERIMENTAL
Intervention: Triclosan toothpaste
Number of subjects: 438

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 438
Study: 25738790

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 25403306

Group type: EXPERIMENTAL
Intervention: Mexidol (1 tablet (125 mg) 3 times a day for 3 weeks) along with standard treatment
Number of subjects: 87

Group type: COMPARATOR
Intervention: Standard treatment only
Number of subjects: 87
Study: 22404194

Group type: EXPERIMENTAL
Intervention: Integrated care by a multidisciplinary team
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integrated care
Number of subjects: 0
Study: 20813517

Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine 1.25mg and sufentanil 5 μg with morphine 50 μg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine 1.25mg and sufentanil 5 μg with morphine 100 μg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intrathecal bupivacaine 1.25mg and sufentanil 5 μg with saline placebo
Number of subjects: 90
Study: 17667145

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study: 15833887

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 125 microg twice daily for 3 weeks and once daily for a fourth week (dosage doubled for infants > or =1200 g)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 11981357

Group type: EXPERIMENTAL
Intervention: 2 NRTIs + 1 protease inhibitor (stavudine + lamivudine + indinavir)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 2 NRTIs + 1 nonnucleoside reverse transcriptase inhibitor (stavudine + didanosine + nevirapine)
Number of subjects: 20
Study: 9887850

Group type: EXPERIMENTAL
Intervention: PrimeTime program (very low‐fat vegetarian diet, smoking cessation, stress‐management training, moderate exercise, and group support)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PrimeTime program
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 100
Study: 8918498

Group type: EXPERIMENTAL
Intervention: Weight-based doses of CAF regimen (cyclophosphamide, doxorubicin, and fluorouracil)
Number of subjects: 1435
Study: 1832302

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 0
Study: 6760379

Group type: EXPERIMENTAL
Intervention: 50 mg trimipramine at bedtime for 4 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 30672979

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: High economic status
Number of subjects: 786
Study: 28371461

Group type: EXPERIMENTAL
Intervention: Insulin glulisine + insulin glargine 300 U/mL (G + G300)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Insulin lispro + insulin glargine biosimilar (L + GB)
Number of subjects: 30
Study: 26924183

Group type: EXPERIMENTAL
Intervention: 20% mannitol
Number of subjects: 38

Group type: COMPARATOR
Intervention: 3.0% hypertonic saline (HTS)
Number of subjects: 38
Study: 23737158

Group type: EXPERIMENTAL
Intervention: Curved stylet
Number of subjects: 40

Group type: COMPARATOR
Intervention: Straight stylet
Number of subjects: 40
Study: 21926570

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-impregnated sponge
Number of subjects: 1636

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-impregnated sponge (3-day dressing change strategy)
Number of subjects: 1636

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-impregnated sponge (7-day dressing change strategy)
Number of subjects: 1636

Group type: COMPARATOR
Intervention: Major catheter-related infection
Number of subjects: 1636
Study: 19232571

Group type: EXPERIMENTAL
Intervention: DBT-based skills training group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study: 17517349

Group type: EXPERIMENTAL
Intervention: Heart Failure Management Program (HFMP) for 6 months
Number of subjects: 190

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 190
Study: 14699366

Group type: EXPERIMENTAL
Intervention: Median and ulnar nerve block
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cooling
Number of subjects: 20
Study: 11472279

Group type: EXPERIMENTAL
Intervention: Music in combination with therapeutic suggestions
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Music and music combined with therapeutic suggestions
Number of subjects: 90

Group type: COMPARATOR
Intervention: Operation room sounds
Number of subjects: 90
Study: 9720727

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Zidovudine and alpha-interferon (proposed treatment)
Number of subjects: 21
Study: 9008769

Group type: EXPERIMENTAL
Intervention: Lobectomy or lesser resection
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pneumonectomy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Whole group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: N0
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: N1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: N2
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Quality of life analysis
Number of subjects: 100
Study: 2805034

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 120 mg daily
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg twice daily
Number of subjects: 17
Study: 961472

Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) administered as a single oral dose with food
Number of subjects: 9

Group type: COMPARATOR
Intervention: Isoniazid (INH) administered as a single oral dose in fasting state
Number of subjects: 9
Study: 31477107

Group type: EXPERIMENTAL
Intervention: Patient-centred mobile application
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Activity tracker (both groups)
Number of subjects: 0
Study: 28483500

Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum NCC3001 (BL)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 26018048

Group type: COMPARATOR
Intervention: MISSION‐Vet Implementation as Usual (IU) - standard training and access to the MISSION‐Vet treatment manuals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MISSION‐Vet implementation augmented by GTO
Number of subjects: 0
Study: 23397296

Group type: EXPERIMENTAL
Intervention: Nasal tramazoline with dexamethasone
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nasal placebo
Number of subjects: 21
Study: 21744976

Group type: EXPERIMENTAL
Intervention: Subliminal distrust priming
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distrust priming (different method)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distrust priming
Number of subjects: 0
Study: 18554601

Group type: EXPERIMENTAL
Intervention: Nifedipine (group A)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Terbutaline (group B)
Number of subjects: 86
Study: 16448302

Group type: EXPERIMENTAL
Intervention: Self-determination theory (SDT) intervention
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Community care (control)
Number of subjects: 1006
Study: 12485379

Group type: EXPERIMENTAL
Intervention: full-coverage hard acrylic splint
Number of subjects: 52

Group type: COMPARATOR
Intervention: palatal-only splint
Number of subjects: 52
Study: 11185998

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) at 1 to 2 g/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conventional oral prednisolone (o‐PSL) (2 mg/kg for 2 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parenteral methylprednisolone (mPSL) (5 mg/kg for 5 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pulsed parenteral methylprednisolone (PmPSL) (30 mg/kg for 3 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 9315400

Group type: EXPERIMENTAL
Intervention: Survey of attitudes and practice
Number of subjects: 0
Study: 8349375

Group type: EXPERIMENTAL
Intervention: gallopamil, 150 mg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: nifedipine, 30 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 3304725

Group type: EXPERIMENTAL
Intervention: Danazol (50 to 600 mg daily for 6 months)
Number of subjects: 25
Study: 31923178

Group type: EXPERIMENTAL
Intervention: Translated reminder letters (Arabic or Italian)
Number of subjects: 1227

Group type: EXPERIMENTAL
Intervention: Reminder telephone calls in preferred language (Arabic or Italian)
Number of subjects: 1227

Group type: COMPARATOR
Intervention: Usual care (no translated letters)
Number of subjects: 1227

Group type: COMPARATOR
Intervention: Usual care (no telephone call)
Number of subjects: 1227
Study: 30646223

Group type: EXPERIMENTAL
Intervention: Online care
Number of subjects: 296

Group type: COMPARATOR
Intervention: In-person care
Number of subjects: 296
Study: 26675778

Group type: EXPERIMENTAL
Intervention: Astaxanthin 12 mg/d
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 24878174

Group type: EXPERIMENTAL
Intervention: Topical ocular hypotensive medications
Number of subjects: 692

Group type: COMPARATOR
Intervention: Control eyes (no treatment)
Number of subjects: 692
Study: 22564825

Group type: EXPERIMENTAL
Intervention: Sexually abused patients
Number of subjects: 125
Study: 20175241

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.4 mu g/kg iv administered over 5 min)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (equal volume to Dex group)
Number of subjects: 30
Study: 17272962

Group type: EXPERIMENTAL
Intervention: 20 mg/d quinapril plus 5 mg/d amlodipine besylate
Number of subjects: 374

Group type: COMPARATOR
Intervention: 40 mg/d quinapril
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 374

Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 374
Study: 15340701

Group type: EXPERIMENTAL
Intervention: Water-jet-cutting tonsillectomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional blunt dissection tonsillectomy
Number of subjects: 60
Study: 12402374

Group type: EXPERIMENTAL
Intervention: Crude allergen extracts from foods
Number of subjects: 292

Group type: COMPARATOR
Intervention: Commercial allergen extracts
Number of subjects: 292
Study: 10449846

Group type: EXPERIMENTAL
Intervention: Gasless laparoscopic cholecystectomy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Low-pressure laparoscopic cholecystectomy
Number of subjects: 36
Study: 7843751

Group type: EXPERIMENTAL
Intervention: 100 mg losartan
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 20 mg enalapril
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 100 mg losartan and 20 mg enalapril
Number of subjects: 51
Study: 2508149

Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: secobarbital
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: marijuana
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 29968290

Group type: EXPERIMENTAL
Intervention: 12-month recall period
Number of subjects: 5000

Group type: COMPARATOR
Intervention: 2-week recall period
Number of subjects: 5000

Group type: COMPARATOR
Intervention: 3-month recall period
Number of subjects: 5000
Study: 28639937

Group type: EXPERIMENTAL
Intervention: IV methylprednisolone plus 2 g/kg of IVIG in divided doses within 5 days of the first commencement of steroid therapy
Number of subjects: 170

Group type: COMPARATOR
Intervention: IV methylprednisolone only
Number of subjects: 170
Study: 26315981

Group type: EXPERIMENTAL
Intervention: Extended-release guanfacine (N=30)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (N=32)
Number of subjects: 62
Study: 23146820

Group type: EXPERIMENTAL
Intervention: 5 mg synthetic oral THC
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 15 mg synthetic oral THC
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Low dose Sativex (5.4 mg THC, 5.0 mg CBD)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High dose Sativex (16.2 mg THC, 15.0 mg CBD)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sativex
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oral THC
Number of subjects: 14
Study: 22027622

Group type: EXPERIMENTAL
Intervention: Erythropoietin (500 IU/kg) and iron sucrose (200 mg)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 74
Study: 19429471

Group type: EXPERIMENTAL
Intervention: Mirtazapine (30 mg oral dose)
Number of subjects: 72
Study: 17021430

Group type: EXPERIMENTAL
Intervention: IMZ SPECT
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: IMZ SPECT, IMP SPECT, FDG PET
Number of subjects: 7
Study: 15158344

Group type: EXPERIMENTAL
Intervention: Standard IFN/ribavirin
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Pegylated-IFN/ribavirin
Number of subjects: 169

Group type: COMPARATOR
Intervention: Serum ferritin
Number of subjects: 169

Group type: COMPARATOR
Intervention: Hepatic iron concentration (HIC)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Transferrin saturation levels
Number of subjects: 169

Group type: COMPARATOR
Intervention: HFE-mutation status
Number of subjects: 169

Group type: COMPARATOR
Intervention: DiBisceglie score
Number of subjects: 169

Group type: COMPARATOR
Intervention: Iron grading
Number of subjects: 169
Study: 11099284

Group type: EXPERIMENTAL
Intervention: Non-directive counselling
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy
Number of subjects: 464

Group type: COMPARATOR
Intervention: Usual general practitioner care
Number of subjects: 464
Study: 9278211

Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg daily for 21 days) + Warfarin (25 mg single dose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Warfarin (25 mg single dose)
Number of subjects: 12
Study: 8338265

Group type: EXPERIMENTAL
Intervention: 1% dextrose in lactated Ringer's solution (RLG1)
Number of subjects: 41

Group type: COMPARATOR
Intervention: 0.9% dextrose in lactated Ringer's solution (B66)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both groups (RLG1 and B66)
Number of subjects: 41
Study: 3495027

Group type: EXPERIMENTAL
Intervention: TMP‐SMZ (50 mg/kg daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: TMP‐SMZ (normal G‐6‐PD)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vancomycin (normal G‐6‐PD)
Number of subjects: 100
Study: 29052439

Group type: EXPERIMENTAL
Intervention: Dual peroxisome proliferator-activated receptor agonist aleglitazar
Number of subjects: 7226

Group type: EXPERIMENTAL
Intervention: N-terminal proB-type natriuretic peptide
Number of subjects: 7226

Group type: EXPERIMENTAL
Intervention: Lack of coronary revascularization
Number of subjects: 7226

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 7226

Group type: EXPERIMENTAL
Intervention: Heart rate
Number of subjects: 7226

Group type: EXPERIMENTAL
Intervention: Glycated haemoglobin
Number of subjects: 7226

Group type: EXPERIMENTAL
Intervention: Haemoglobin
Number of subjects: 7226

Group type: EXPERIMENTAL
Intervention: Prior coronary artery bypass
Number of subjects: 7226

Group type: EXPERIMENTAL
Intervention: Prior myocardial infarction
Number of subjects: 7226
Study: 27160738

Group type: EXPERIMENTAL
Intervention: Concurrent Treatment (motor learning-based treatment)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (treatment if needed after the study)
Number of subjects: 28
Study: 23928955

Group type: EXPERIMENTAL
Intervention: Combined general with spinal anesthesia
Number of subjects: 38

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 38
Study: 22951500

Group type: EXPERIMENTAL
Intervention: Calcitonin (200 IU/d)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Etidronate (400 mg/d orally for 14 days quarterly)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/d)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Calcium plus Vitamin D3 (1000 mg/d calcium plus 800 IU/d vitamin D3)
Number of subjects: 222
Study: 20102746

Group type: EXPERIMENTAL
Intervention: Tacrolimus + Mycophenolate Mofetil (MMF)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Tacrolimus + Methotrexate (MTX)
Number of subjects: 89
Study: 18202889

Group type: EXPERIMENTAL
Intervention: Primary duct closure
Number of subjects: 80

Group type: COMPARATOR
Intervention: T‐tube drainage
Number of subjects: 80